University of California, Santa Barbara, CA 93106, USA.
Expert Rev Vaccines. 2010 Feb;9(2):157-73. doi: 10.1586/erv.09.160.
Considerable success has been made with many peptide antigen formulations, and peptide-based vaccines are emerging as the next generation of prophylactic and remedial immunotherapy. However, finding an optimal platform balancing all of the requirements for an effective, specific and safe immune response remains a major challenge for many infectious and chronic diseases. This review outlines how peptide immunogenicity is influenced by the way in which peptides are presented to the immune system, underscoring the need for multifunctional delivery systems that couple antigen and adjuvant into a single construct. Particular attention is given to the ability of Toll-like receptor agonists to act as adjuvants. A survey of recent approaches to developing peptide antigen delivery systems is given, many of which incorporate Toll-like receptor agonists into the design.
在许多肽抗原制剂方面已经取得了相当大的成功，基于肽的疫苗正在成为下一代预防性和治疗性免疫疗法。然而，找到一个平衡有效、特异性和安全性免疫反应所有要求的最佳平台仍然是许多传染病和慢性疾病的主要挑战。本综述概述了肽免疫原性如何受到肽向免疫系统呈递方式的影响，强调需要将抗原和佐剂结合成单一构建体的多功能递药系统。特别关注 Toll 样受体激动剂作为佐剂的能力。本文对开发肽抗原递药系统的最新方法进行了调查，其中许多方法将 Toll 样受体激动剂纳入设计中。
